Dr. Marie Wikström Lindholm currently serves as VP, Head of Molecular Design for Silence Therapeutics, where she has been for the past 2 years. With over 13 years of experience in her field, she leads an interdisciplinary innovation team of 12 and bounces between the roles of scientist and drug developer. She is hands on in the development of new therapeutic oligonucleotides as well as in strategy and planning for the research part of the company.
Marie earned her PhD in Medical Chemistry at Uppsala University, did a postdoc in Berkeley, and eventually returned to Sweden and an academic career in Experimental Cardiovascular Science at the Faculty of Medicine, Lund University. In addition to the ISFP, she is a member of the American Heart Association and the Oligonucleotide Therapeutic Society, and has to date published 42 peer reviewed papers as well as co-authored a long list of patent applications.
Recently Marie started a side business; Maclawili (www.maclawili.se). The company is a scientific consultancy, founded in response to frequently getting asked for scientific input in her areas of expertise. Maclawili is a way of sharing decades of experience in a manner that doesn´t get in the way of her day job.
A fact-driven scientist at heart, she has advanced to a position where she is leading teams of skilled specialists. She would like to continue to grow professionally while making sound contributions in applied science. She sometimes gets frustrated about what she perceives to be a glass ceiling, and would like to bounce experiences off of other women in the field. She credits her success to being open to new opportunities and not afraid of change.